Content
Prescription weight loss that puts you first
Side-by-side medication summaries to compare approved uses, side effects, interactions, and more.
Content
Rybelsus
Wegovy
Rybelsus® (semaglutide) is an oral medication used to improve blood sugar control in adults with type 2 diabetes. It is the first glucagon-like peptide-1 (GLP-1) receptor agonist available in tablet form. It stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying to lower blood sugar levels. Rybelsus is taken once daily and can be used alone or in combination with other diabetes medications, along with diet and exercise. Common side effects include nausea, diarrhea, and abdominal pain, and it should be used cautiously in patients with a history of pancreatitis.
Wegovy® (semaglutide) is an injectable medication approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol. It works by mimicking the hormone glucagon-like peptide-1 (GLP-1), which regulates appetite and food intake, leading to reduced calorie consumption and significant weight loss. Wegovy is administered once weekly and is intended to be used in conjunction with a reduced-calorie diet and increased physical activity. Common side effects include nausea, diarrhea, vomiting, and constipation. It should be used with caution in patients with a history of pancreatitis and is not recommended for use in pregnant or breastfeeding individuals​.
Prescription
Prescription
Glucagon-like peptide-1 (GLP-1) receptor agonist
Glucagon-like peptide-1 (GLP-1) receptor agonist
Rybelsus (semaglutide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Wegovy (semaglutide) is indicated in combination with a reduced calorie diet and increased physical activity:
To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
To reduce excess body weight and maintain weight reduction long term in:
Adults and pediatric patients aged 12 years and older with obesity
Adults with overweight in the presence of at least one weight-related comorbid condition
Typically taken orally once daily
Comes in 3 mg, 7 mg, and 14 mg tablets
Typically taken as an injection once weekly
Comes in single-dose pens that deliver 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg per injection
Most common adverse reactions (incidence ≥5%) are:
Nausea
Abdominal pain
Diarrhea
Decreased appetite
Vomiting
Constipation
Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are:
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Headache
Fatigue
Indigestion
Dizziness
Abdominal distension
Belching
Low blood sugar in patients with type 2 diabetes
Flatulence
Inflammation of the digestive system
Gastroesophageal reflux disease (heartburn)
Inflammation of the nasal cavities and back of the throat
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Prior serious hypersensitivity reaction to semaglutide or any of the excipients in Rybelsus
Drug interactions: Oral Medications—Rybelsus delays gastric emptying
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Known hypersensitivity to semaglutide or any of the excipients in Wegovy
Drug interactions: Wegovy delays gastric emptying. May impact absorption of concomitantly administered oral medications
Pancreatitis
Diabetic retinopathy complications
Low blood sugar: Concomitant use with an insulin secretagogue or insulin may increase the risk of low blood sugar, including severe low blood sugar
Acute kidney injury
Hypersensitivity reactions
Acute gallbladder disease
Pregnancy: May cause fetal harm
Lactation: Breastfeeding not recommended
Females and males of reproductive potential: Discontinue Rybelsus in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide
Acute pancreatitis
Acute gallbladder disease
Low blood sugar: Concomitant use with insulin or an insulin secretagogue may increase the risk of low blood sugar, including severe low blood sugar
Acute kidney injury
Hypersensitivity reactions
Diabetic retinopathy complications in patients with type 2 diabetes
Heart rate increase
Suicidal behavior and ideation
Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy
Females and males of reproductive potential: Discontinue Wegovy at least 2 months before a planned pregnancy because of the long half-life of semaglutide
WARNING: RISK OF THYROID C-CELL TUMORS
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether Rybelsus causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Rybelsus is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
WARNING: RISK OF THYROID C-CELL TUMORS
In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Wegovy is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
*This information is from the label for brand name Rybelsus®. See the Full Prescribing Information for more complete information. Semaglutide, the active ingredient in Rybelsus, is also the active ingredient in other brand-name medications, including Ozempic® and Wegovy®, and this information may not be accurate for all medications that include the active ingredient semaglutide.
*This information is from the label for brand name Wegovy®. See the Full Prescribing Information for more complete information. Semaglutide, the active ingredient in Wegovy, is also the active ingredient in other brand-name medications, including Ozempic® and Rybelsus®, and this information may not be accurate for all medications that include the active ingredient semaglutide.
The information provided here is NOT MEDICAL ADVICE and is for informational and educational purposes only. The drug comparison tool does not determine eligibility for medications or treatments provided via the Hims/Hers platform. Consultation with a healthcare provider is required to assess suitability for any medical treatment based on individual health and medical history. All product names and associated trademarks are the property of their respective owners.